Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMDNASDAQ:MNPRNASDAQ:PHVSNASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$13.98+6.1%$9.93$3.61▼$13.98$948.19M1.621.19 million shs2.52 million shsMNPRMonopar Therapeutics$37.11-2.4%$36.89$1.72▼$54.30$226.93M1.11358,739 shs19,857 shsPHVSPharvaris$16.78+4.5%$15.52$11.51▼$25.50$877.43M-2.8675,100 shs82,545 shsSNDXSyndax Pharmaceuticals$11.45+2.6%$11.32$8.58▼$25.07$985.24M0.821.79 million shs1.34 million shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix+6.46%+7.86%+18.10%+23.06%+148.68%MNPRMonopar Therapeutics+6.80%+17.35%-2.90%+33.65%+844.35%PHVSPharvaris-3.43%-4.01%-4.63%+6.93%-2.73%SNDXSyndax Pharmaceuticals+1.82%+5.08%+4.89%-16.84%-41.91%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRMDCorMedix0.5199 of 5 stars1.61.00.00.02.60.00.6MNPRMonopar Therapeutics2.9612 of 5 stars3.45.00.00.02.62.50.0PHVSPharvaris1.8642 of 5 stars3.53.00.00.02.10.80.0SNDXSyndax Pharmaceuticals3.143 of 5 stars3.51.00.04.42.20.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 3.14Buy$15.007.30% UpsideMNPRMonopar Therapeutics 2.75Moderate Buy$55.3349.11% UpsidePHVSPharvaris 3.00Buy$37.25121.99% UpsideSNDXSyndax Pharmaceuticals 2.91Moderate Buy$35.91213.62% UpsideCurrent Analyst Ratings BreakdownLatest MNPR, SNDX, CRMD, and PHVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2025PHVSPharvarisWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$27.005/14/2025PHVSPharvarisCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$28.00 ➝ $25.005/7/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $15.005/6/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.005/6/2025SNDXSyndax PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$16.00 ➝ $17.005/6/2025SNDXSyndax PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/29/2025PHVSPharvarisCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$28.004/9/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/8/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.004/2/2025MNPRMonopar TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/1/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.00(Data available from 6/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$82.55M11.49N/AN/A$1.28 per share10.92MNPRMonopar TherapeuticsN/AN/AN/AN/A$1.88 per shareN/APHVSPharvarisN/AN/AN/AN/A$7.95 per shareN/ASNDXSyndax Pharmaceuticals$43.72M22.53N/AN/A$6.53 per share1.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix-$46.34M$0.22N/A14.87N/AN/A-79.21%-64.68%8/13/2025 (Estimated)MNPRMonopar Therapeutics-$8.40M-$3.48N/AN/AN/AN/A-107.21%-87.57%8/8/2025 (Estimated)PHVSPharvaris-$109.18M-$3.01N/AN/AN/AN/A-38.52%-36.69%8/13/2025 (Estimated)SNDXSyndax Pharmaceuticals-$209.36M-$3.86N/AN/AN/AN/A-64.34%-57.72%8/7/2025 (Estimated)Latest MNPR, SNDX, CRMD, and PHVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MNPRMonopar Therapeutics-$0.65-$0.38+$0.27-$0.38N/AN/A5/13/2025Q1 2025PHVSPharvaris-$0.80-$0.89-$0.09-$0.89N/AN/A5/6/2025Q1 2025CRMDCorMedix$0.25$0.30+$0.05$0.30$38.90 million$39.08 million5/5/2025Q1 2025SNDXSyndax Pharmaceuticals-$1.04-$0.98+$0.06-$0.98$15.88 million$20.04 million4/7/2025Q4 2024PHVSPharvaris-$0.74-$0.68+$0.06-$0.68N/AN/A3/31/2025Q4 2024MNPRMonopar Therapeutics-$0.36-$2.23-$1.87-$2.23N/AN/A3/25/2025Q4 2024CRMDCorMedix$0.17$0.22+$0.05$0.22$27.46 million$30.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/APHVSPharvarisN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedixN/A3.963.60MNPRMonopar TherapeuticsN/A5.415.41PHVSPharvarisN/A19.0819.08SNDXSyndax PharmaceuticalsN/A6.996.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%MNPRMonopar Therapeutics1.83%PHVSPharvarisN/ASNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCRMDCorMedix5.30%MNPRMonopar Therapeutics20.50%PHVSPharvaris11.84%SNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3067.83 million57.52 millionOptionableMNPRMonopar Therapeutics106.12 million3.97 millionNot OptionablePHVSPharvaris3052.29 million46.10 millionNot OptionableSNDXSyndax Pharmaceuticals11086.05 million81.86 millionOptionableMNPR, SNDX, CRMD, and PHVS HeadlinesRecent News About These CompaniesSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 5 at 4:01 PM | globenewswire.comAmeriprise Financial Inc. Has $423,000 Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)June 5 at 3:14 AM | marketbeat.comKura Posts New Data, Secures NDA Acceptance in Acute Myeloid Leukemia Race With SyndaxJune 3 at 1:17 PM | biospace.comNuveen Asset Management LLC Trims Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)June 1, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Bank of America Corp DEJune 1, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Wellington Management Group LLPMay 31, 2025 | marketbeat.comVoloridge Investment Management LLC Takes $1.05 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 31, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 4.9% - Still a Buy?May 30, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $35.91 Average Target Price from BrokeragesMay 30, 2025 | americanbankingnews.comSyndax Announces Participation in June Investor ConferencesMay 29, 2025 | globenewswire.comPolar Asset Management Partners Inc. Invests $1.12 Million in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 29, 2025 | marketbeat.comMillennium Management LLC Has $7.76 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 28, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 28, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Two Sigma Investments LPMay 27, 2025 | marketbeat.comTwo Sigma Advisers LP Has $7.09 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 26, 2025 | marketbeat.com121,539 Shares in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Acquired by Man Group plcMay 26, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 5.7% - Here's WhyMay 25, 2025 | marketbeat.comTwinbeech Capital LP Boosts Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 23, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Lowers Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 23, 2025 | marketbeat.comSoleus Capital Management L.P. Boosts Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)May 21, 2025 | marketbeat.comSyndax Pharmaceuticals Inc.May 21, 2025 | wsj.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNPR, SNDX, CRMD, and PHVS Company DescriptionsCorMedix NASDAQ:CRMD$13.98 +0.80 (+6.07%) Closing price 04:00 PM EasternExtended Trading$13.92 -0.05 (-0.39%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Monopar Therapeutics NASDAQ:MNPR$37.11 -0.90 (-2.37%) Closing price 04:00 PM EasternExtended Trading$37.08 -0.02 (-0.07%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Pharvaris NASDAQ:PHVS$16.78 +0.73 (+4.55%) Closing price 04:00 PM EasternExtended Trading$17.50 +0.72 (+4.29%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.Syndax Pharmaceuticals NASDAQ:SNDX$11.45 +0.29 (+2.60%) Closing price 04:00 PM EasternExtended Trading$11.44 0.00 (-0.04%) As of 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
